Accession Number PB2014-100663
Title Guidance for Industry: Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring.
Publication Date Aug 2013
Media Count 22p
Personal Author N/A
Abstract Effective monitoring of clinical investigations by sponsors is critical to the protection of human subjects and the conduct of high-quality studies. Sponsors of clinical investigations involving human drugs, biological products, medical devices, and combinations thereof are required to provide oversight to ensure adequate protection of the rights, welfare, and safety of human subjects and the quality of the clinical trial data submitted to FDA. FDA's regulations require sponsors to monitor the conduct and progress of their clinical investigations. The regulations are not specific about how sponsors are to conduct such monitoring and are therefore compatible with a range of approaches to monitoring (see section III) that will vary depending on multiple factors (see section IV.C).
Keywords Biological products
Clinical trials
Consumer protection
Drugs
Humans
Industry guidance
Investigations
Medical devices
Monitoring
Regulations
Risk
Safety


 
Source Agency Center for Devices and Radiological Health
NTIS Subject Category 57Q - Pharmacology & Pharmacological Chemistry
57E - Clinical Medicine
96D - Consumer Affairs
Corporate Author Food and Drug Administration, Rockville, MD. Center for Biologics Evaluation and Research.
Document Type Technical report
Title Note N/A
NTIS Issue Number 1401
Contract Number N/A

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader